Email updates

Keep up to date with the latest news and content from European Journal of Medical Research and BioMed Central.

Open Access Research

Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study

P Cuevas1*, W Espinoza2, C Pérez3, J Angulo1 and C Giménez-Gallego4

Author Affiliations

1 Departamento de Investigación. Servicio de Histología. IRYCIS. Hospital Universitario Ramón y Cajal, Madrid

2 Servicio de Dermatología. Hospital Universitario Ramón y Cajal. Madrid

3 Servicio de Farmacia. Hospital Universitario Ramón y Cajal. Madrid

4 Departamento de Biología Fisico-Química, Centro de Investigaciones Biológicas Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

For all author emails, please log on.

European Journal of Medical Research 2011, 16:67-70  doi:10.1186/2047-783X-16-2-67

Published: 24 February 2011

Abstract

Background

Fibroblast growth factor (FGF) is involved in skin tumorigenesis: it promotes cell viability, induces angiogenesis and stimulates invasiveness. Dobesilate is a drug that blocks the activity of FGF. The primary objective was to evaluate the efficacy and tolerability of potassium dobesilate 5% cream in the treatment of actinic keratoses.

Methods

Potassium dobesilate 5% cream was applied twice daily for 16 weeks to actinic keratosis lesions in 30 patients. The lesions were evaluated clinically at an initial baseline visit, at intermediate visits, and at 16 weeks of treatment.

Results

The use of potassium dobesilate 5% cream for 16 weeks induced complete regression in 70% of evaluated actinic keratoses, corresponding to grade I, II and III clinical variants, and a partial response (at least 75% reduction of lesions) in 20% of the cases.

Conclusion

Our preliminary trial shows that potassium dobesilate exerts anti-tumorigenic effects and may play a useful role in the chemoprevention of skin cancers.

Keywords:
Actinic keratosis; Dobesilate; Fibroblast growth factor